Eli Lilly sued six retatrutide sellers. Here’s the documented record.

On August 12, 2026 Eli Lilly filed six federal lawsuits over retatrutide — four against research-use-only peptide vendors, one med spa, one compounding pharmacy. We track it from the dockets and update as filings land.

The six cases

What Lilly alleges

That the “research use only” label was a pretext — that the sellers supplied dosing instructions, ran consumer-facing storefronts without prescriptions, and served buyers who intended to inject the compound themselves. Retatrutide is still in Phase 3 and is not approved by any regulator anywhere in the world.

The framing is the story: no patent claims, no trademark claims in any of the six. Lilly pleaded state consumer-protection statutes across seven states plus Texas common law. The RUO disclaimer isn’t being treated as a defence — it’s being treated as the misrepresentation.

These are allegations. No defendant has been found liable, and none has filed a public denial as of this update.

Docket updates

• Aug 12 — six complaints filed; Lilly calls on platforms, payment processors and regulators to act, citing 14,000+ listings reported and 200+ referrals to authorities.
• Aug 19 / Aug 25 — Aesthetic Envy and Striker Pharmacy execute waivers of service; responses land roughly mid-to-late October.
• Aug 27 — Fifth Circuit affirms for FDA in the tirzepatide compounding appeal.
• Aug 31 — Lilly files an amended complaint against Astra LLC.
• Sept 24 — Seventh Circuit oral argument, Lilly v. FDA, on whether retatrutide is a biologic.

What it changes for this index

None of the vendors priced on this board is a defendant, and none of the compounds we index — BPC-157, TB-500, GHK-Cu and the rest — is the subject of these filings. What changes is the standard. These companies were not sued over product quality. They were sued over how they marketed it. Price still matters; so does whether a vendor publishes real third-party testing and keeps its research-use framing honest.

Full breakdown with every source: the complete tracker on Peptides Uncaged →  ·  Peptide Deal Board

Court records reviewed September 1, 2026 via CourtListener/RECAP. Every characterisation of Lilly’s case is an allegation contained in its complaints. Vial Prices is not a party to these actions and has no relationship with any defendant. Journalism, not legal advice.